ClinicalTrials.gg
CompletedNCT05266404Updated Jul 5, 2022

Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

A Phase 1 interventional study of Dapagliflozin/sitagliptin FDC and Sitagliptin in Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus), sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-05.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
128th of 180
46 · median 82
Started
2022
with 9 others
Phase 1
26 of 180
none open now
Registered
152nd of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 128th largest by enrollment, is one of 10 that started in 2022, is one of 26 in phase 1, and was the 152nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A Study to Assess the Bioequivalence of the fixed dose combination (FDC) of Dapagliflozin and Sitagliptin, and Dapagliflozin 10 mg and Sitagliptin 100 mg administered as individual tablets in Healthy Subject

Read the detailed description

This study will be a randomized, open-label, 2-period, 2-treatment, single-dose, crossover study in healthy subjects (males and females), performed at a single study center. The study will assess the bioequivalence between a dapagliflozin/sitagliptin FDC tablet (test formulation) and a free combination of dapagliflozin 10 mg + sitagliptin 100 mg co-administered as individual tablets (reference formulation) in fasted conditions to healthy subjects. The study will also assess the Pharmacokinetics (PK) and safety and tolerability of dapagliflozin 10 mg and sitagliptin 100 mg when co-administered as individual tablets and as an FDC tablet.

The study will comprise:

  • A Screening Period of maximum 28 days.
  • Two Treatment Periods (Treatment A or B)
  • A final Safety Follow-up Visit 7 to 14 days after the last dosing with the Investigational medicinal product (IMP) (Treatment A or B).

There will be a minimum washout period of 7 days and a maximum of 14 days between each treatment period.

All subjects will receive a single dose of the following treatments after an overnight fast of 10 hours:

  • Treatment A: 1 × dapagliflozin/sitagliptin FDC tablet (test formulation).
  • Treatment B: 1 × dapagliflozin 10 mg tablet + 1 × sitagliptin 100 mg tablet co-administered as individual tablets (reference formulation).

Subjects will be randomized to one of 2 treatment sequences: Treatment A followed by Treatment B or Treatment B followed by Treatment A.

03

Conditions studied

  • Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Keywords

  • Sodium-glucose co-transporter-2 (SGLT2) inhibitor
  • Dipeptidyl peptidase 4 (DPP4) inhibitor
  • fixed dose combination (FDC)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture.
  • Females must have a negative serum pregnancy test at Screening and negative urine pregnancy test within 24 hours prior to Medicinal product (IMP) administration, and must be of non .

    1. defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.

      Or, if of childbearing potential:

    3. Must not be nursing (breastfeeding).
    4. If heterosexually active, must agree to consistently use an acceptable method of , to avoid pregnancy from at least 4 weeks prior to the first administration of IMP through 90 days after the last dose of IMP.
  • Sexually active fertile male subject with partners of childbearing potential must adhere to the contraception methods during the study and until 90 days after the last dose of IMP.
  • Have a between 18.5 and 30 kg/m\^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  • Current or recent (within 3 months of the first IMP dose) gastrointestinal disease that may impact drug absorption and affect the PK of the IMP. Additionally, any gastrointestinal surgery (eg, partial gastrectomy or pyloroplasty), including cholecystectomy, that may impact drug absorption.
  • Any major surgery within 4 months of the first IMP dose.
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of Screening.
  • Donation of > 400 mL of blood within 8 weeks or donation of plasma (except at Screening) within 4 weeks of the first IMP dose.
  • Blood transfusion within 4 weeks of the first IMP dose.
  • Inability to tolerate oral medication.
  • Inability to tolerate venipuncture or inadequate venous access.
  • Recent drug or alcohol abuse.
  • Excessive intake of alcohol.
  • Excessive intake of caffeine-containing drinks or food.
  • Use of tobacco-containing or nicotine-containing products.
  • History of impaired glucose metabolism.
  • Recent vulvovaginal mycotic infections (within 2 months prior to first IMP dose).
  • Any other sound medical, psychiatric, and/or social reason, as determined by the Investigator.
  • Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, at Screening and/or admission to the Clinical Unit.
  • Any clinically significant abnormal findings in vital signs at Screening and/or admission to the Clinical Unit.
  • Any clinically significant abnormalities on 12-lead at Screening
  • Any positive result on screening for serum surface antigen or anti-hepatitis core antibody, antibody, and antibody.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first IMP dose in this study.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to dapagliflozin and sitagliptin or to any of the .
  • Positive screen for drugs of abuse at Screening or on each admission to the Clinical Unit or positive screen for alcohol on each admission to the Clinical Unit.
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first IMP dose.
  • Use of any prescription drugs or OTC acid controllers within 4 weeks prior to the first IMP dose. Use of any prescribed or non-prescribed medication including analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins, and minerals during the 2 weeks prior to the first IMP dose or longer if the medication has a long half-life.
  • Subjects who have previously received dapagliflozin or sitagliptin.
  • Subjects who had a severe course of COVID-19 (extracorporeal membrane oxygenation, mechanically ventilated).
  • Subjects who had the last dose of the COVID-19 vaccine within 7 days of Screening.
  • Recent (within 14 days prior to Screening) exposure to someone who has COVID 19 symptoms or positive test results for COVID-19.
  • Recent (within 14 days prior to Screening) visit to a healthcare facility where patients with COVID-19 are being treated.
  • Subjects who are regularly exposed to COVID-19 as part of their daily life (eg, health care professionals working in COVID-19 wards or at emergency departments).
  • Subjects who have positive test results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via reverse transcriptase polymerase chain reaction (RT-PCR) before randomization.
  • Subject has clinical signs and symptoms consistent with COVID-19 infection or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission.
  • Involvement of any AstraZeneca, Parexel, or study site employee or their close relatives.
  • Judgment by the Investigator that the subject should not participate in the study if they have any ongoing or recent (ie, during Screening) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Subjects who cannot communicate reliably with the Investigator.
  • Vulnerable subjects, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Treatment A (Test Formulation): Dapagliflozin/Sitagliptin FDC tablet

    Subjects will receive single dose of dapagliflozin/sitagliptin fixed dose combination (FDC) (test formulation).

    Drug: Dapagliflozin/sitagliptin FDC

  • Active comparator
    Treatment B (Reference Formulation): Dapagliflozin+Sitagliptin

    Subjects will receive single dose of dapagliflozin 10 mg tablet + sitagliptin 100 mg tablet co-administered as individual tablets (reference formulation).

    Drug: Sitagliptin · Drug: Dapagliflozin

Interventions

  • DrugDapagliflozin/sitagliptin FDC

    Drug pages: Dapagliflozin · Sitagliptin

    Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.

  • Subjects will receive 100 mg single dose of Sitagliptin orally.

    Also known as: JANUVIA™

  • Subjects will receive 10 mg single dose of Dapagliflozin orally.

    Also known as: FORXIGA™

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from zero to infinity (AUCinf)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  2. Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  3. Maximum observed plasma (peak) drug concentration (Cmax)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  4. Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  5. Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  6. Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRTinf)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  7. Terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  8. Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  9. Volume of distribution (apparent) following extravascular administration (based on terminal phase) (Vz/F)

    To demonstrate the fasted-state bioequivalence between a dapagliflozin/sitagliptin FDC tablet relative to dapagliflozin 10 mg + sitagliptin 100 mg when co administered as individual tablets in healthy subjects.

    Time frame: Day 1, Day 2, Day 3 and Day 4

Secondary outcomes

  1. Area under plasma concentration-time curve from zero to infinity (AUCinf)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  2. Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  3. Maximum observed plasma (peak) drug concentration (Cmax)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  4. Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  5. Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  6. Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRTinf)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  7. Terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  8. Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  9. Volume of distribution (apparent) following extravascular administration (based on terminal phase) (Vz/F)

    To characterize the PK profiles of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects in a fasted state.

    Time frame: Day 1, Day 2, Day 3 and Day 4

  10. Number of subjects with adverse events (AEs)

    To assess the safety and tolerability of single doses of a dapagliflozin/sitagliptin FDC tablet and dapagliflozin 10 mg + sitagliptin 100 mg when co-administered as individual tablets in healthy subjects.

    Time frame: From screening (Day -28) to Safety Follow-up (7 to 14 days after the last dosing with the IMP) [up to 66 days]

07

Study locations

1 site
  • Research Site
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2022, 2 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2022
First posted
Mar 4, 2022
StartActual
Mar 21, 2022
Primary completionActual
May 31, 2022
CompletionActual
May 31, 2022
Last update
Jul 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05266404
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Mar 21, 2022
Primary completion
May 31, 2022
Completion
May 31, 2022
Last update
Jul 5, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Sitagliptin

Start the discussion